Nefazodone
Alternative Names: BMY 13754; Dutonin; MJ 13754; MS 13754; Nefadar; SERZONELatest Information Update: 05 Nov 2023
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Menarini; Merck KGaA; Mitsubishi Pharma Corporation; Teva Pharmaceutical Industries
- Class Antidepressants; Small molecules; Triazoles
- Mechanism of Action Adrenergic receptor antagonists; Serotonin 5-HT2 receptor antagonists; Serotonin 5-HT2A receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Market Withdrawal Major depressive disorder
- Discontinued Panic disorder
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 29 Jun 2004 Discontinued - Phase-II for Depression in Japan (PO)
- 29 Jun 2004 Discontinued - Phase-III for Panic disorder in Europe (PO)